Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Approval Of Novartis' Everolimus Could Mean mTOR Inhibitor Class REMS

Executive Summary

The likely approval of Novartis' everolimus for prevention of kidney transplant rejection could bring with it safety labeling updates and Risk Evaluation and Mitigation Strategies for all drugs in the mTOR inhibitor class

You may also be interested in...



Imposing Everolimus REMS On Sirolimus Rests On If There Is New Safety Info

The approval of Novartis' Zortress (everolimus) with a Risk Evaluation and Mitigation Strategy has opened up an FDA review of whether Pfizer's Rapamune (sirolimus), from which everolimus is derived, should have a similar plan

Imposing Everolimus REMS On Sirolimus Rests On If There Is New Safety Info

The approval of Novartis' Zortress (everolimus) with a Risk Evaluation and Mitigation Strategy has opened up an FDA review of whether Pfizer's Rapamune (sirolimus), from which everolimus is derived, should have a similar plan

Panel Recommends Novartis' Kidney Transplant Drug Certican

Taking the panel's previous advice to demonstrate everolimus' efficacy with lower doses of cyclosporine is what gained the committee endorsement Dec. 7.

Related Content

Topics

UsernamePublicRestriction

Register

PS051750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel